313 related articles for article (PubMed ID: 26361993)
1. An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules.
Stegert M; Kasenda B; von Elm E; You JJ; Blümle A; Tomonaga Y; Saccilotto R; Amstutz A; Bengough T; Briel M;
J Clin Epidemiol; 2016 Jan; 69():152-60. PubMed ID: 26361993
[TBL] [Abstract][Full Text] [Related]
2. Reporting on data monitoring committees in neonatal randomised controlled trials is inconsistent.
Perrem LM; Gosling S; Ravikumar I; Khashan AS; Miletin J; Ryan CA; Dempsey E
Acta Paediatr; 2017 Jan; 106(1):30-33. PubMed ID: 27637413
[TBL] [Abstract][Full Text] [Related]
3. Data monitoring committees, interim analysis and early termination in paediatric trials.
Fernandes RM; van der Lee JH; Offringa M
Acta Paediatr; 2011 Oct; 100(10):1386-92. PubMed ID: 21434998
[TBL] [Abstract][Full Text] [Related]
4. Recruitment failure and futility were the most common reasons for discontinuation of clinical drug trials. Results of a nationwide inception cohort study in the Netherlands.
van den Bogert CA; Souverein PC; Brekelmans CTM; Janssen SWJ; Koëter GH; Leufkens HGM; Bouter LM
J Clin Epidemiol; 2017 Aug; 88():140-147. PubMed ID: 28487159
[TBL] [Abstract][Full Text] [Related]
5. Premature Discontinuation of Pediatric Randomized Controlled Trials: A Retrospective Cohort Study.
Schandelmaier S; Tomonaga Y; Bassler D; Meerpohl JJ; von Elm E; You JJ; Bluemle A; Lamontagne F; Saccilotto R; Amstutz A; Bengough T; Stegert M; Olu KK; Tikkinen KAO; Neumann I; Carrasco-Labra A; Faulhaber M; Mulla SM; Mertz D; Akl EA; Sun X; Busse JW; Ferreira-González I; Nordmann A; Gloy V; Raatz H; Moja L; Rosenthal R; Ebrahim S; Vandvik PO; Johnston BC; Walter MA; Burnand B; Schwenkglenks M; Hemkens LG; Guyatt G; Bucher HC; Kasenda B; Briel M
J Pediatr; 2017 May; 184():209-214.e1. PubMed ID: 28410086
[TBL] [Abstract][Full Text] [Related]
6. Randomized trials stopped early for benefit: a systematic review.
Montori VM; Devereaux PJ; Adhikari NK; Burns KE; Eggert CH; Briel M; Lacchetti C; Leung TW; Darling E; Bryant DM; Bucher HC; Schünemann HJ; Meade MO; Cook DJ; Erwin PJ; Sood A; Sood R; Lo B; Thompson CA; Zhou Q; Mills E; Guyatt GH
JAMA; 2005 Nov; 294(17):2203-9. PubMed ID: 16264162
[TBL] [Abstract][Full Text] [Related]
7. Early stopping rules in oncology: considerations for clinicians.
Mukherjee SD; Goffin JR; Taylor V; Anderson KK; Pond GR
Eur J Cancer; 2011 Nov; 47(16):2381-6. PubMed ID: 21684153
[TBL] [Abstract][Full Text] [Related]
8. Inefficacy interim monitoring procedures in randomized clinical trials: the need to report.
Korn EL; Freidlin B
Am J Bioeth; 2011 Mar; 11(3):2-10. PubMed ID: 21400374
[TBL] [Abstract][Full Text] [Related]
9. Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility.
Walter SD; Han H; Briel M; Guyatt GH
Stat Med; 2017 Apr; 36(9):1506-1518. PubMed ID: 28183155
[TBL] [Abstract][Full Text] [Related]
10. Premature trial discontinuation often not accurately reflected in registries: comparison of registry records with publications.
Alturki R; Schandelmaier S; Olu KK; von Niederhäusern B; Agarwal A; Frei R; Bhatnagar N; Hooft L; von Elm E; Briel M
J Clin Epidemiol; 2017 Jan; 81():56-63. PubMed ID: 27614277
[TBL] [Abstract][Full Text] [Related]
11. A systematic survey of randomised trials that stopped early for reasons of futility.
Walter SD; Han H; Guyatt GH; Bassler D; Bhatnagar N; Gloy V; Schandelmaier S; Briel M
BMC Med Res Methodol; 2020 Jan; 20(1):10. PubMed ID: 31948397
[TBL] [Abstract][Full Text] [Related]
12. Randomized trials stopped early for harm in HIV/AIDS: a systematic survey.
Mills E; Cooper C; Wu P; Rachlis B; Singh S; Guyatt GH
HIV Clin Trials; 2006; 7(1):24-33. PubMed ID: 16684642
[TBL] [Abstract][Full Text] [Related]
13. Prevalence, characteristics, and publication of discontinued randomized trials.
Kasenda B; von Elm E; You J; Blümle A; Tomonaga Y; Saccilotto R; Amstutz A; Bengough T; Meerpohl JJ; Stegert M; Tikkinen KA; Neumann I; Carrasco-Labra A; Faulhaber M; Mulla SM; Mertz D; Akl EA; Bassler D; Busse JW; Ferreira-González I; Lamontagne F; Nordmann A; Gloy V; Raatz H; Moja L; Rosenthal R; Ebrahim S; Schandelmaier S; Xin S; Vandvik PO; Johnston BC; Walter MA; Burnand B; Schwenkglenks M; Hemkens LG; Bucher HC; Guyatt GH; Briel M
JAMA; 2014 Mar; 311(10):1045-51. PubMed ID: 24618966
[TBL] [Abstract][Full Text] [Related]
14. Learning from failure--rationale and design for a study about discontinuation of randomized trials (DISCO study).
Kasenda B; von Elm EB; You J; Blümle A; Tomonaga Y; Saccilotto R; Amstutz A; Bengough T; Meerpohl J; Stegert M; Tikkinen KA; Neumann I; Carrasco-Labra A; Faulhaber M; Mulla S; Mertz D; Akl EA; Bassler D; Busse JW; Ferreira-González I; Lamontagne F; Nordmann A; Rosenthal R; Schandelmaier S; Sun X; Vandvik PO; Johnston BC; Walter MA; Burnand B; Schwenkglenks M; Bucher HC; Guyatt GH; Briel M
BMC Med Res Methodol; 2012 Aug; 12():131. PubMed ID: 22928744
[TBL] [Abstract][Full Text] [Related]
15. Reporting of data monitoring boards in publications of randomized clinical trials is often deficient: ACTTION systematic review.
Gewandter JS; Kitt RA; Hunsinger MR; Poku J; Lozano J; Chaudari J; Evans S; Gross RA; McDermott MP; Rowbotham MC; Turk DC; Dworkin RH
J Clin Epidemiol; 2017 Mar; 83():101-107. PubMed ID: 28126598
[TBL] [Abstract][Full Text] [Related]
16. Premature Discontinuation of Randomized Trials in Critical and Emergency Care: A Retrospective Cohort Study.
Schandelmaier S; von Elm E; You JJ; Blümle A; Tomonaga Y; Lamontagne F; Saccilotto R; Amstutz A; Bengough T; Meerpohl JJ; Stegert M; Olu KK; Tikkinen KA; Neumann I; Carrasco-Labra A; Faulhaber M; Mulla SM; Mertz D; Akl EA; Sun X; Bassler D; Busse JW; Ferreira-González I; Nordmann A; Gloy V; Raatz H; Moja L; Rosenthal R; Ebrahim S; Vandvik PO; Johnston BC; Walter MA; Burnand B; Schwenkglenks M; Hemkens LG; Cook DJ; Meade MO; Bucher HC; Kasenda B; Briel M
Crit Care Med; 2016 Jan; 44(1):130-7. PubMed ID: 26468895
[TBL] [Abstract][Full Text] [Related]
17. Stopping guidelines for an effectiveness trial: what should the protocol specify?
Tyson JE; Pedroza C; Wallace D; D'Angio C; Bell EF; Das A
Trials; 2016 May; 17(1):240. PubMed ID: 27165260
[TBL] [Abstract][Full Text] [Related]
18. The role of the Data and Safety Monitoring Board in a clinical trial: the CRISIS study.
Holubkov R; Casper TC; Dean JM; Anand KJ; Zimmerman J; Meert KL; Newth CJ; Berger J; Harrison R; Willson DF; Nicholson C;
Pediatr Crit Care Med; 2013 May; 14(4):374-83. PubMed ID: 23392377
[TBL] [Abstract][Full Text] [Related]
19. Comparison of futility monitoring guidelines using completed phase III oncology trials.
Zhang Q; Freidlin B; Korn EL; Halabi S; Mandrekar S; Dignam JJ
Clin Trials; 2017 Feb; 14(1):48-58. PubMed ID: 27590208
[TBL] [Abstract][Full Text] [Related]
20. Stopping rules, interim analyses and data monitoring committees.
Ashby D; Machin D
Br J Cancer; 1993 Dec; 68(6):1047-50. PubMed ID: 8260354
[No Abstract] [Full Text] [Related]
[Next] [New Search]
